AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31359271 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone/9-OH-RIS ratio
Number of subjects: 71
Study 31524664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arm cycling and task-oriented exercises
Number of subjects: 20
Study 31524664 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 29630457 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians rating the acceptability of withholding surgery when prognosis is certain to be poor.
Number of subjects: 818
Study 29630457 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclinicians rating the acceptability of withholding surgery.
Number of subjects: 818
Study 29630457 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians rating the acceptability of withholding surgery based on prognosis certainty.
Number of subjects: 818
Study 29630457 — intervention group
Group type: COMPARATOR
Intervention: Effect of surrogate distress on clinician ratings.
Number of subjects: 818
Study 26177825 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention including education, counseling, and social support (16 days over the first 2 years)
Number of subjects: 236
Study 26177825 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 236
Study 26177825 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 236
Study 24984211 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral
Number of subjects: 12000
Study 24984211 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12000
Study 22340088 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-component environmental intervention at the worksite level over a two-year period.
Number of subjects: 6
Study 22340088 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group.
Number of subjects: 6
Study 20576364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 20576364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17416764 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise training
Number of subjects: 32
Study 17416764 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle (control)
Number of subjects: 32
Study 17416764 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in lean body mass over the intervention
Number of subjects: 32
Study 16360084 — intervention group
Group type: EXPERIMENTAL
Intervention: Early protocol (shock delivered mean 6.8 hours after AF onset)
Number of subjects: 44
Study 16360084 — intervention group
Group type: COMPARATOR
Intervention: Delayed protocol (shock delivered mean 34.7 hours after AF onset)
Number of subjects: 44
Study 12441805 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (short course)
Number of subjects: 185
Study 10732590 — intervention group
Group type: EXPERIMENTAL
Intervention: Haid holder
Number of subjects: 68
Study 10732590 — intervention group
Group type: COMPARATOR
Intervention: Other tube holders
Number of subjects: 68
Study 7773832 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA with in‐hospital and post discharge management by a home intervention team (HIT)
Number of subjects: 540
Study 7773832 — intervention group
Group type: COMPARATOR
Intervention: CGA with recommendations and usual care at home
Number of subjects: 540
Study 7773832 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital and home care
Number of subjects: 540
Study 2338688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of nitrendipine, atenolol, and hydrochlorothiazide
Number of subjects: 24
Study 2338688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations containing hydrochlorothiazide
Number of subjects: 24
Study 117482 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 13
Study 117482 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 13
Study 117482 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Volunteers)
Number of subjects: 13
Study 117482 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 13
Study 117482 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine vs Amoxapine
Number of subjects: 13
Study 31057081 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Health (mHealth) intervention
Number of subjects: 30
Study 31057081 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up group
Number of subjects: 30
Study 30707179 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 164
Study 30707179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 164
Study 30707179 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 164
Study 30707179 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical controls
Number of subjects: 164
Study 30707179 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1 year postoperatively)
Number of subjects: 164
Study 28682972 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency energy
Number of subjects: 40
Study 28682972 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 40
Study 26000757 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-E
Number of subjects: 130
Study 26000757 — intervention group
Group type: COMPARATOR
Intervention: IPT
Number of subjects: 130
Study 23873561 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (MYO) supplementation
Number of subjects: 1200
Study 23873561 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial phytase supplementation
Number of subjects: 1200
Study 23873561 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol and microbial phytase supplementation (simultaneously)
Number of subjects: 1200
Study 23873561 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with lower Ca and dP concentration
Number of subjects: 1200
Study 21803850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 278
Study 21803850 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine alone
Number of subjects: 278
Study 19090549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing EPA (33 patients)
Number of subjects: 52
Study 19090549 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 patients)
Number of subjects: 52
Study 16982225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0
Study 16982225 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 12573305 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal patients with depression
Number of subjects: 35
Study 12573305 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal controls
Number of subjects: 35
Study 12573305 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal patients with depression
Number of subjects: 35
Study 10720131 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alfa treatment
Number of subjects: 71
Study 10720131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic remission
Number of subjects: 71
Study 10720131 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cytogenetic remission
Number of subjects: 71
Study 10720131 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotype responses
Number of subjects: 71
Study 8836226 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward Walking (FW)
Number of subjects: 10
Study 8836226 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward Walking (BW)
Number of subjects: 10
Study 1413984 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (0; 1.12; 2.24; 3.37 g n-3 FA/day)
Number of subjects: 58
Study 1413984 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (3.37 g n-3 FA/day)
Number of subjects: 58
Study 1413984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 3863197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg PGE2 triacetin gel administered twice over a 12 hour period
Number of subjects: 0
Study 3863197 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg PGE2 triacetin gel administered as a single dose
Number of subjects: 0
Study 31994519 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program including psychopharmacological, psychotherapeutic and socio‐therapeutic procedures
Number of subjects: 128
Study 31994519 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 128
Study 29689122 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Group A)
Number of subjects: 161
Study 29689122 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Group C)
Number of subjects: 161
Study 29689122 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group B)
Number of subjects: 161
Study 26459161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb
Number of subjects: 94
Study 26459161 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 94
Study 26459161 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 94
Study 25747752 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 26
Study 25747752 — intervention group
Group type: COMPARATOR
Intervention: Untrained (UT)
Number of subjects: 26
Study 23733273 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated adventure-based training and health education program
Number of subjects: 71
Study 23733273 — intervention group
Group type: COMPARATOR
Intervention: Control group (received same amount of time and attention without specific effect)
Number of subjects: 71
Study 21940729 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone therapy for 24 weeks
Number of subjects: 93
Study 21940729 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 93
Study 19423946 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,800 mg of eicosapentaenoic acid (EPA) + statin
Number of subjects: 1050
Study 19423946 — intervention group
Group type: COMPARATOR
Intervention: statin alone (control group)
Number of subjects: 1050
Study 16977362 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized bovine-prepared fibrin glue
Number of subjects: 22
Study 16977362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 22
Study 14628190 — intervention group
Group type: EXPERIMENTAL
Intervention: Zydis Selegiline 1.25 mg
Number of subjects: 197
Study 14628190 — intervention group
Group type: EXPERIMENTAL
Intervention: Zydis Selegiline 10 mg
Number of subjects: 197
Study 14628190 — intervention group
Group type: COMPARATOR
Intervention: Zydis Selegiline 5 mg
Number of subjects: 197
Study 14628190 — intervention group
Group type: COMPARATOR
Intervention: Conventional selegiline tablets 10 mg
Number of subjects: 197
Study 10877128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pustulosis palmoplantaris
Number of subjects: 12
Study 10877128 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized pustular psoriasis
Number of subjects: 12
Study 9276109 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Vagus Nerve Stimulation (VNS)
Number of subjects: 8
Study 8061382 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose gadoteridol (0.3 mmol/kg total: 0.1 mmol/kg + 0.2 mmol/kg)
Number of subjects: 9
Study 8061382 — intervention group
Group type: COMPARATOR
Intervention: Single-dose gadoteridol (0.1 mmol/kg)
Number of subjects: 9
Study 3195807 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 11
Study 3195807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31741283 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free hydrocortisone 0.335% for 12 days four times daily followed by 2 days twice daily instillation (intense treatment group)
Number of subjects: 60
Study 31741283 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free hydrocortisone 0.335% for 8 days three times daily followed by 3 days twice daily treatment (standard treatment group)
Number of subjects: 60
Study 29871697 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm cranking exercise
Number of subjects: 34
Study 29871697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 34
Study 29871697 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 28612179 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10 1000 mg
Number of subjects: 154
Study 28612179 — intervention group
Group type: COMPARATOR
Intervention: RTX 1000 mg
Number of subjects: 154
Study 28612179 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 154
Study 28612179 — intervention group
Group type: COMPARATOR
Intervention: RTX
Number of subjects: 154
Study 25527766 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 whole-body UVB treatments with a total dose of 6 or 7.5 standard erythema doses during a 10-day period
Number of subjects: 92
Study 25527766 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D₃-fortified bread and milk
Number of subjects: 92
Study 25458157 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 0
Study 25458157 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg
Number of subjects: 0
Study 22984466 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised normative feedback (PNF) provided by email
Number of subjects: 1751
Study 22984466 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 1751
Study 22984466 — intervention group
Group type: COMPARATOR
Intervention: Delayed measurement control group
Number of subjects: 1751
Study 20307624 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate RDA toothpaste
Number of subjects: 20
Study 20307624 — intervention group
Group type: EXPERIMENTAL
Intervention: High RDA toothpaste
Number of subjects: 20
Study 20307624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RDA toothpaste
Number of subjects: 20
Study 20307624 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 20
Study 18771373 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, 500 mg, every 12 hours for six doses
Number of subjects: 8
Study 18771373 — intervention group
Group type: COMPARATOR
Intervention: Control site (healthy gingiva)
Number of subjects: 8
Study 15653658 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-DOTATOC (8.1-22.9 GBq)
Number of subjects: 18
Study 12204968 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) 600 mg/day, Nelfinavir (NFV) 750 mg three times daily, Stavudine (d4T) 30 or 40 mg twice daily
Number of subjects: 18
Study 12204968 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV), Nelfinavir (NFV), and Stavudine (d4T) therapy
Number of subjects: 18
Study 9973070 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified randomization
Number of subjects: 0
Study 9097333 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured empowerment programme with a trained psychologist during 20 weekly 1-hour sessions
Number of subjects: 0
Study 9097333 — intervention group
Group type: COMPARATOR
Intervention: Control group passively attended by the psychologist during equal time conditions
Number of subjects: 0
Study 8412364 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrate suppositories
Number of subjects: 19
Study 8412364 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine suppositories
Number of subjects: 19
Study 8412364 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional therapy for pouchitis discontinued)
Number of subjects: 19
Study 3531373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 3531373 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 3531373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29409128 — intervention group
Group type: EXPERIMENTAL
Intervention: Project MOVE
Number of subjects: 72
Study 27061338 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 22
Study 27061338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24398824 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine extended-release (XR) (50 to 300 mg daily)
Number of subjects: 90
Study 24398824 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (10 to 75 mg daily)
Number of subjects: 90
Study 24398824 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine extended-release (XR)
Number of subjects: 90
Study 24398824 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 90
Study 22349808 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuvatinib DPC with high-fat meal
Number of subjects: 58
Study 22349808 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuvatinib LSC (single-dose)
Number of subjects: 58
Study 22349808 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuvatinib LSC 300 mg every 8 h (multiple-dose)
Number of subjects: 58
Study 22349808 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 58
Study 20297950 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (145 mg NanoCrystal tablet)
Number of subjects: 34
Study 20297950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18356266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose transpupillary thermotherapy (TTT)
Number of subjects: 98
Study 18356266 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 98
Study 15664306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (8 g per day)
Number of subjects: 77
Study 15664306 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo, 8 g per day)
Number of subjects: 77
Study 15664306 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Fish oil and Olive oil)
Number of subjects: 77
Study 12452875 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream 3 days per week with occlusion
Number of subjects: 183
Study 12452875 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream 3 days per week without occlusion
Number of subjects: 183
Study 10328192 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate 4 times a day for 3 months
Number of subjects: 40
Study 10328192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7585833 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g daily for 10 days)
Number of subjects: 17
Study 7585833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8417865 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2 mg daily
Number of subjects: 32
Study 8417865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8417865 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2 mg daily after placebo
Number of subjects: 32
Study 3542091 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFL) 24 mg/day
Number of subjects: 12
Study 3542091 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (Pd) 20 mg/day
Number of subjects: 12
Study 29053977 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 29053977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 29053977 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI Subjective Depression
Number of subjects: 0
Study 29053977 — intervention group
Group type: EXPERIMENTAL
Intervention: HDRS Psychic Depression, BDI Subjective Depression, BDI Self-Blame
Number of subjects: 0
Study 26024583 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux biliary stent (group B)
Number of subjects: 16
Study 26024583 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Tannenbaum stent (group A)
Number of subjects: 16
Study 25237481 — intervention group
Group type: EXPERIMENTAL
Intervention: Community treatment orders (CTOs)
Number of subjects: 333
Study 25237481 — intervention group
Group type: COMPARATOR
Intervention: Community mental health teams' approach
Number of subjects: 333
Study 22708645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine + placebo
Number of subjects: 86
Study 22708645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine + placebo (BD I subgroup)
Number of subjects: 86
Study 22708645 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine + divalproex ER
Number of subjects: 86
Study 22708645 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine + divalproex ER (BD I subgroup)
Number of subjects: 86
Study 19842011 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (titrated up to a maximum of 400 mg/day over 4 weeks)
Number of subjects: 13
Study 19842011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19842011 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 13
Study 18852316 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical natural language processing method for extracting trial participants
Number of subjects: 223
Study 18852316 — intervention group
Group type: COMPARATOR
Intervention: Manual identification of trial participants
Number of subjects: 223
Study 16022951 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-microg dose in the 30-day release group
Number of subjects: 244
Study 16022951 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-microg dose in the 30-day release group
Number of subjects: 244
Study 16022951 — intervention group
Group type: COMPARATOR
Intervention: Bare metal Conor stent
Number of subjects: 244
Study 16022951 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluting stent group
Number of subjects: 244
Study 16022951 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day release groups (0% and 3.4%)
Number of subjects: 244
Study 12459617 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) using glass-ionomer
Number of subjects: 835